News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MGI Pharma (MOGN) To Acquire Zycos; Pivotal Phase 3 Program For ZYC101 A Planned For Early 2005; $50 Million In Cash



10/19/2005 5:10:29 PM

MGI PHARMA, INC. (Nasdaq:MOGN), an oncology-focused biopharmaceutical company, and Zycos Inc., a privately held company focused on the creation and development of oncology and antiviral products, today announced that they have signed a definitive merger agreement under which MGI PHARMA will acquire Zycos for $50 million in cash. This transaction, which has been approved by the boards of directors of both companies, is subject to approval by the stockholders of Zycos. MGI PHARMA and Zycos expect the transaction to close in September 2004.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES